跳至主要内容

Medicilon won the "Best Strategic Partner" award from NewDEL Biotech in 2023

 Shanghai Medicilon Inc. (Medicilon) has recently won the "Best Partner Award" from Gluetacs Therapeutics and the "2003 Best Partner Award" from SicaGene.

On January 29, Medicilon was awarded the 2023 "Best Strategic Partner" award by NewDEL Biotech.

honor.webp

Trust makes each other successful, Collaboration creates the future

NewDEL Biotech is the first biopharmaceutical company incubated by the Guangdong Small Molecule New Drug Innovation Center (Small Molecule Center).  Relying on the independently developed "SmartDEL technology platform" and unique living cell screening technology, a full life cycle system for innovative drugs focusing on the design, development and industrialization of FIC innovative drugs has been established to target unmet clinical needs.  In addition, dozens of R&D pipelines have been laid out.  It can be said that "innovation" has become the foundation and confidence for the development of NewDEL Biology.

Like NewDEL Biotech, Medicilon also adheres to integrity and innovation, and has successfully established a one-stop biopharmaceutical preclinical R&D service platform.  Relying on this platform, Medicilon has provided strong support for the research and development of new drugs by NewDEL Biotech.  Since the collaboration, the two parties have faced many challenges, made a lot of gratifying progress, and moved forward together.

Find more about Preclinical Research Platform: 

https://www.medicilon.com/platform/preclinical-research-services/

About NewDEL Biotech

NewDEL Biotech was established in April 2021. It is an industrialized company incubated and controlled by the Guangdong Small Molecule New Drug Innovation Center.  Relying on its independently developed "SmartDEL technology platform" and unique living cell screening technology, NewDEL Biotech has established a full life cycle system for innovative drugs focusing on the design, development and industrialization of FIC innovative drugs for unmet clinical needs.  NewDEL Biotech committed to become an internationally leading and distinctive new drug R&D biopharmaceutical company.

About Medicilon

Since the founding of our company in 2004, Medicilon (Stock Code: 688202.SH) has grown into one of the professional drug discovery contract research organizations (CRO) in China.  Over the years, Medicilon keeps improving their services in biotechnology and pharmaceutical research.  Their services now span across medicinal chemistry, process chemistry, in vitro and in vivo DMPK, preclinical development and bioanalytical support.  By the end of June 2023, Medicilon has provided new drug R&D services to more than 2,000 clients around the world, and participated in the R&D of 420 new drug projects that have been approved for clinical trials.  Medicilon is proud to contribute to human health in the globe.

标签：

评论

发表评论

此博客中的热门博文

What is preclinical testing?

In the process of  preclinical testing  of a compound or biological agent into a drug, the compound involved must go through the testing phase. First, we need to identify potential targets that can treat the disease. Then, a variety of compounds or preparations are screened out. Any compound that has shown potential as a drug for the treatment of this disease needs to be tested for toxicity before clinical testing to reduce the possibility of injury. preclinical testing What is the basis of preclinical testing? According to US Food and Drug Administration (FDA) regulations, a series of tests are required before a new drug is approved for use. In the first stage, basic research determines a hypothetical target for the treatment of a certain disease, and then screens small molecules or biological compounds to discover any substance with the potential to treat the disease. Then, a  preclinical research  phase followed, before which, as described above, the potential toxicity of the compou
发表评论
阅读全文

Inventory of the three major in vitro pharmacokinetic research methods

  The metabolic properties of a compound are an essential factor in whether or not it can be used as a drug in the clinical setting, so pharmacokinetic studies of newly synthesized compounds are required in drug development. In vitro incubation with liver microsomes, recombinant CYP450 enzyme lines, and in vitro incubation with hepatocytes are some of the more common in vitro drug metabolism methods. 1. In vitro incubation method with liver microsomes The metabolic stability and metabolic phenotypes of candidate compounds in different species of liver microsomes are good predictors of the metabolic properties of compounds in vivo. They are practical tools for evaluating candidate compounds in the pre-development phase of drug development. Liver microsomes include rat liver microsomes, human liver microsomes, canine liver microsomes, monkey liver microsomes, and mouse liver microsomes. In in vitro incubation of the liver, microsomes are the "gold standard" for in vitro d
发表评论
阅读全文

Enzyme Activity Assay Service

  Enzymatic assay Lance Assay Alphascreen Assay Z’-LYTE Assay Adapta Assay Kinase-Glo Assay ADP-Glo Assay Ligand Binding Assay ELISA Assay HTRF Assay Enzyme activity assays  are laboratory methods for measuring enzymatic activity. They are vital for the study of enzyme kinetics and enzyme inhibition. Enzyme units : Amounts of enzymes can either be expressed as molar amounts, as with any other chemical, or measured in terms of activity, in enzyme units. Medicilon provides various  enzyme activity assays  for  kinases , phosphatases, proteinases, deacetylase, peptidase, esterase, and other enzymes. Our line of well-characterized immunoassays and biochemical kits ensures accurate and reproducible results. Enzyme is a  large category of bio-molecules  that catalyze various biological processes including metabolic processes, cellular signaling and regulation, cell division and apoptosis. Enzymatic reactions convert substrate molecules into chemically modified molecules products with high sp
发表评论
阅读全文